OXOLIFE

OXOLIFE is a pioneering Spanish biotech addressing a critical unmet need in reproductive medicine: the lack of treatments to improve embryo implantation, which accounts for approximately 50% of pregnancy losses in IVF cycles. Its lead candidate, OXO-001, is an oral, non-hormonal pill that acts directly on the uterine lining and has demonstrated efficacy in increasing implantation and pregnancy rates in a Phase II trial. The company is also exploring OXO-001's potential to treat infertility in PCOS patients, positioning itself in the high-growth femtech and fertility markets with a first-in-class therapeutic approach.

First-in-class, non-hormonal oral small molecule drug (OXO-001) designed to directly target the endometrium to enhance embryo implantation and improve reproductive outcomes.

OXOLIFE's OXO-001 is a first-in-class candidate with no direct marketed competitors for enhancing implantation. Competition exists from various procedural and adjunctive therapies in IVF (e.g., endometrial scratching, adjuvant heparin) and from companies developing other novel implantation therapies, but the oral, non-hormonal mechanism is a key differentiator. In PCOS, it would compete with symptomatic treatments but aims to directly address the underlying infertility.